3 completed, 2 not yet recruiting, 2 recruiting, 1 active not recruiting. 3 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Not yet recruiting 2, Recruiting 1 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Acute Promyelocytic Leukemia (APL): new trials by email Literature Review of Acute Promyelocytic Leukemia (APL) trials Research Report on Acute Promyelocytic Leukemia (APL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-20 |
| A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA) - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Not yet recruiting | SDK Therapeutics, Inc. | 120 | 2026-01-01 | 2025-12-29 |
| AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment Unaided Review First, Then AI-Assisted Review, AI-Assisted Review First, Then Unaided Review - Acute Promyelocytic Leukemia (APL), Acute Myeloid Leukaemia (AML) | Not applicable | Completed | Harvard Medical School (HMS and HSDM) | 10 | 2025-09-09 | 2025-10-31 |
| Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia Venetoclax, All-trans retinoic acid, Arsenic Trioxide (ATO) - Acute Promyelocytic Leukemia (APL) | Not applicable | Active not recruiting | Anhui Medical University | 28 | 2025-07-01 | 2025-09-23 |
| Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL) | Phase 1 | Completed | SDK Therapeutics, Inc. | 12 | 2025-03-11 | 2025-11-18 |
| Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia Realgar-Indigo Naturalis Formulation - Acute Promyelocytic Leukemia (APL) | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 115 | 2023-10-20 | 2025-05-30 |
| Red Cell Transfusion Goals in Patients With Acute Leukemias Red blood cell transfusion - Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia (ALL) | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 90 | 2014-04-01 | 2019-01-24 |
| Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia (APL) | Terminated | Skyline Diagnostics BV | 264 | 2011-10-01 | 2013-05-29 |
Leukemia, Promyelocytic, Acute (9) · Leukemia, Myeloid, Acute (3) · Leukemia (2) · Anemia, Refractory, with Excess of Blasts (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (9) · Leukemia, Myeloid (9) · Neoplasms by Histologic Type (9) · Hematologic Diseases (8) · Neoplasms (8) · Leukemia (7) · Leukemia, Myeloid, Acute (6) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1)
Arsenic Trioxide (4) · Tretinoin (3) · Arsenic (1) · Erythrocyte Transfusion (1) · Lisaftoclax (1) · venetoclax (1)
SDK Therapeutics, Inc. (2) · Anhui Medical University (1) · Harvard Medical School (HMS and HSDM) (1) · Instituto do Cancer do Estado de São Paulo (1) · Quetzal Therapeutics (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Skyline Diagnostics BV (1) · The Affiliated People's Hospital of Ningbo University (1)
United States (4) · Brazil (1) · China (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Romania (1) · Spain (1) · United Kingdom (1)
Alan Burnett, MD (1) · Amy DeZern, MD, MHS (1) · Bob Lowenberg, MD (1) · Eduardo M Rego, MD PhD (1) · Guido Marcucci, MD (1) · Hartmut Doehner, MD (1) · Martin Tallman, MD (1) · Zhangbiao Long (1)
PMID 27198129, PMID 34932836, PMID 41114449
2025 (2)